Benzinga | Jan 10, 2022 08:39AM EST

Barclays Maintains Underweight on Chimera Investment, Raises Price Target to $14

Barclays maintains Chimera Investment (NYSE:CIM) with a Underweight and raises the price target from $11 to $14.